FDA Updates Articles
The U.S. Food and Drug Administration (FDA) has determined that hydroxyethyl starch (HES) solutions should not be used in critically ill adult patients, including patients with sepsis and those admitted to the intensive care unit (ICU).
The U.S. Food and Drug Administration(FDA) has approved an expanded indication for CSL Behring’s Corifact, factor XIII (FXIII) concentrate (human) to include the perioperative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.
VARIZIG, a hyperimmune globulin indicated for post-exposure prophylaxis of varicella zoster virus (VZV) in high-risk patients, has been approved by the U.S.Food and Drug Administration.
The U.S. Food and Drug Administration has approved a new children’s vaccine that targets two common causes of bacterial meningitis.
Octapharma USA’s Octaplas, a solvent/detergent-treated pooled human plasma, has been approved by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children ages 3 and older and adults against flu virus subtypes A and B.
Baxter International has received U.S. Food and Drug Administration approval for a 4,000 IU dosage of Advate (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free Method).
